About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 369202, 6 pages
http://dx.doi.org/10.1155/2013/369202
Review Article

How to Translate Basic Knowledge into Clinical Application of Biologic Therapy in Spondyloarthritis

Division of Allergy-Immunology-Rheumatology, Department of Medicine, Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei 112, Taiwan

Received 7 November 2012; Accepted 24 May 2013

Academic Editor: Jieruo Gu

Copyright © 2013 Chung-Tei Chou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Sieper, J. Braun, M. Rudwaleit, A. Boonen, and A. Zink, “Ankylosing spondylitis: an overview,” Annals of the Rheumatic Diseases, vol. 61, supplement 3, pp. iii8–iii18, 2002. View at Scopus
  2. M. A. Khan and S. M. van der Linden, “Ankylosing spondylitis and other spondyloarthropathies,” Rheumatic Disease Clinics of North America, vol. 16, no. 3, pp. 551–579, 1990. View at Scopus
  3. X. Baraliakos and J. Braun, “Spondyloarthritides,” Best Practice and Research: Clinical Rheumatology, vol. 25, no. 6, pp. 825–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. L.-S. Tam, J. Gu, and D. Yu, “Pathogenesis of ankylosing spondylitis,” Nature Reviews Rheumatology, vol. 6, no. 7, pp. 399–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Zochling, D. van der Heijde, R. Burgos-Vargas et al., “ASAS/EULAR recommendations for the management of ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 442–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Braun, R. Van Den Berg, X. Baraliakos et al., “2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 896–904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Ash, C. Gaujoux-Viala, L. Gossec et al., “A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 71, no. 3, pp. 319–326, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Braun, J. Zochling, X. Baraliakos et al., “Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1147–1153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Haibel, M. Rudwaleit, J. Braun, and J. Sieper, “Six months open label trial of leflunomide in active ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 124–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Haibel, H. C. Brandt, I. H. Song et al., “No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial,” Annals of the Rheumatic Diseases, vol. 66, no. 3, pp. 419–421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Hetland, I. J. Christensen, U. Tarp et al., “Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 22–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Emery, F. Breedveld, D. van der Heijde et al., “Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study,” Arthritis and Rheumatism, vol. 62, no. 3, pp. 674–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Sieper, “Developments in therapies for spondyloarthritis,” Nature Reviews Rheumatology, vol. 8, no. 5, pp. 280–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Schett, “Osteoimmunology in rheumatic diseases,” Arthritis Research and Therapy, vol. 11, no. 1, article 210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Braun, M. Bollow, L. Neure et al., “Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 38, no. 4, pp. 499–505, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. W. S. Chen, C. H. Chen, K. C. Lin et al., “Immunohistological features of hip synovitis in ankylosing spondylitis with advanced hip involvement,” Scandinavian Journal of Rheumatology, vol. 38, no. 2, pp. 154–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-T. Chou, C.-Y. Tsai, T.-H. Liang et al., “Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis,” Modern Rheumatology, vol. 20, no. 6, pp. 580–587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. H. Hsiao, C. Y. Tsai, T. M. Chang, et al., “Significant decrease in serum IL-6 and MMP-3 after treatment in ankylosing spondylitis patients,” Formosan Journal of Rheumatology, vol. 25, pp. 11–19, 2011.
  19. C. Henderson and J. C. Davis, “Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis,” Nature Clinical Practice Rheumatology, vol. 2, no. 4, pp. 211–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Rudwaleit, X. Baraliakos, J. Listing, J. Brandt, J. Sieper, and J. Braun, “Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept,” Annals of the Rheumatic Diseases, vol. 64, no. 9, pp. 1305–1310, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Haringman, D. M. Gerlag, A. H. Zwinderman et al., “Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 834–838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Izquierdo, J. D. Cañete, R. Celis et al., “Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy,” Arthritis and Rheumatism, vol. 63, no. 9, pp. 2575–2583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Baeten, E. Kruithof, F. van den Bosch, et al., “Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study,” Arthritis and Rheumatism, vol. 44, no. 1, pp. 186–195, 2001.
  24. A. W. R. van Kuijk, D. M. Gerlag, K. Vos et al., “A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1303–1309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-H. Chen, H.-A. Chen, H.-T. Liao, C.-H. Liu, C.-Y. Tsai, and C.-T. Chou, “Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation,” Clinical Rheumatology, vol. 29, no. 10, pp. 1155–1161, 2010. View at Scopus
  26. N. Busquets-Perez, H. Marzo-Ortega, and P. Emery, “Emerging drugs for axial spondyloarthritis including ankylosing spondylitis,” Expert Opinion on Emerging Drugs, vol. 18, no. 1, pp. 71–86, 2013. View at Publisher · View at Google Scholar
  27. F. K. Tan and K. Farheen, “The potential importance of Toll-like receptors in ankylosing spondylitis,” International Journal of Clinical Rheumatology, vol. 6, no. 6, pp. 649–654, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Akira, “Mammalian Toll-like receptors,” Current Opinion in Immunology, vol. 15, no. 1, pp. 5–11, 2003. View at Publisher · View at Google Scholar
  29. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at Scopus
  30. S. H. Hwang, H. Lee, M. Yamamoto, et al., “B cell TLR7 expression drives anti-RNA autoantibody production and exacerbates disease in systemic lupus erythematosus-prone mice,” The Journal of Immunology, vol. 189, no. 12, pp. 5786–5796, 2012. View at Publisher · View at Google Scholar
  31. C. Zhao, J. Liao, W. Chu, et al., “Involvement of TLR2 and TLR4 and Th1/Th2 shift in inflammatory responses induced by fine ambient particulate matter in mice,” Inhalation Toxicology, vol. 24, no. 13, pp. 918–927, 2012. View at Publisher · View at Google Scholar
  32. Z. Shi, Z. Cai, J. Yu, et al., “Toll-like receptor 11 (TLR11) prevents Salmonella penetration into the murine Peyer patches,” The Journal of Biological Chemistry, vol. 287, no. 52, pp. 43417–43423, 2012. View at Publisher · View at Google Scholar
  33. L. de Rycke, B. Vandooren, E. Kruithof, F. de Keyser, E. M. Veys, and D. Baeten, “Tumor necrosis factor α blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy,” Arthritis and Rheumatism, vol. 52, no. 7, pp. 2146–2158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. Z.-X. Yang, Y. Liang, Y. Zhu et al., “Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis,” Clinical and Experimental Immunology, vol. 149, no. 1, pp. 48–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Baeten, P. Demetter, C. A. Cuvelier et al., “Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammaton in spondyloarthropathy,” Journal of Pathology, vol. 196, no. 3, pp. 343–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Kruithof, D. Baeten, L. de Rycke et al., “Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R569–R580, 2005. View at Scopus
  37. D. Baeten, E. Kruithof, L. de Rycke et al., “Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy,” Arthritis Research & Therapy, vol. 7, no. 2, pp. R359–R369, 2005. View at Scopus
  38. T. Noordenbos, N. Yeremenko, I. Gofita et al., “Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis,” Arthritis and Rheumatism, vol. 64, no. 1, pp. 99–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. Ulevitch, “Therapeutics targeting the innate immune system,” Nature Reviews Immunology, vol. 4, no. 7, pp. 512–520, 2004. View at Scopus
  40. J. Leipe, M. Grunke, C. Dechant et al., “Role of Th17 cells in human autoimmune arthritis,” Arthritis and Rheumatism, vol. 62, no. 10, pp. 2876–2885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Lubberts, “Th17 cytokines and arthritis,” Seminars in Immunopathology, vol. 32, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Jandus, G. Bioley, J.-P. Rivals, J. Dudler, D. Speiser, and P. Romero, “Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2307–2317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. W. S. Chen, Y. S. Chang, K. C. Lin, et al., “Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis,” Journal of the Chinese Medical Association, vol. 75, no. 7, pp. 303–308, 2012. View at Publisher · View at Google Scholar
  45. G. Layh-Schmitt and R. A. Colbert, “The interleukin-23/interleukin-17 axis in spondyloarthritis,” Current Opinion in Rheumatology, vol. 20, no. 4, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Mei, F. Pan, J. Gao, et al., “Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis,” Clinical Rheumatology, vol. 30, no. 2, pp. 269–273, 2011. View at Publisher · View at Google Scholar
  47. H. Shen, J. C. Goodall, and J. S. Hill Gaston, “Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis,” Arthritis and Rheumatism, vol. 60, no. 6, pp. 1647–1656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Singh, A. Aggarwal, and R. Misra, “Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy,” Journal of Rheumatology, vol. 34, no. 11, pp. 2285–2290, 2007. View at Scopus
  49. E. Lee, W. L. Trepicchio, J. L. Oestreicher et al., “Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris,” Journal of Experimental Medicine, vol. 199, no. 1, pp. 125–130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Wang, Z. Lin, Q. Wei, Y. Jiang, and J. Gu, “Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis,” Rheumatology International, vol. 29, no. 11, pp. 1343–1347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Baeten, J. Sieper, P. Emery, et al., “The anti-IL-17A monoclonal antibody secukinumab(AIN457)shoewd good safety and efficacy in the treatment of active ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 70, no. 3, p. 127, 2011.
  52. H. Ikeuchi, T. Kuroiwa, N. Hiramatsu et al., “Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1037–1046, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. S. C. Liang, X.-Y. Tan, D. P. Luxenberg et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides,” Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271–2279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Zheng, D. M. Danilenko, P. Valdez et al., “Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature, vol. 445, no. 7128, pp. 648–651, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Zhang, Y.-G. Li, Y.-H. Li et al., “Increased frequencies of th22 cells as well as th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis,” PLoS One, vol. 7, no. 4, Article ID e31000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. É. Toussirot, “The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases,” Inflammation and Allergy—Drug Targets, vol. 11, no. 2, pp. 159–168, 2012. View at Scopus
  57. J. Gratacos, A. Collado, X. Filella et al., “Serum cytokines (IL-6, TNF-α, IL-β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity,” British Journal of Rheumatology, vol. 33, no. 10, pp. 927–931, 1994. View at Scopus
  58. H.-A. Chen, C.-H. Chen, H.-T. Liao et al., “Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis,” Seminars in Arthritis and Rheumatism, vol. 40, no. 6, pp. 552–558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. S. J. Pedersen, M. L. Hetland, I. J. Sørensen, M. Østergaard, H. J. Nielsen, and J. S. Johansen, “Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors,” Clinical Rheumatology, vol. 29, no. 11, pp. 1301–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. J. A. Schafer, N. K. Kjesbo, and P. P. Gleason, “Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis,” Journal of Managed Care Pharmacy, vol. 16, no. 6, pp. 402–416, 2010. View at Scopus
  61. S. Rajalingham and S. Das, “Antagonizing IL-6 in ankylosing spondylitis: a short review,” Inflammation & Allergy-Drug Targets, vol. 11, no. 4, pp. 262–265, 2012. View at Publisher · View at Google Scholar
  62. J.-D. Cohen, R. Ferreira, and C. Jorgensen, “Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab,” Journal of Rheumatology, vol. 38, no. 7, p. 1527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Koumakis, A. Feydy, A. Kahan, and Y. Allanore, “Interleukin 6 blockade in spondyloarthritis,” The Journal of Rheumatology, vol. 39, no. 5, pp. 1097–1098, 2012. View at Publisher · View at Google Scholar
  64. G. Schett, “Joint remodelling in inflammatory disease,” Annals of the Rheumatic Diseases, vol. 66, supplement 3, pp. iii42–iii44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Diarra, M. Stolina, K. Polzer et al., “Dickkopf-1 is a master regulator of joint remodeling,” Nature Medicine, vol. 13, no. 2, pp. 156–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Beyer and J. H. Distler, “Changing paradigms in spondylarthritis: the myofibroblast signature,” Arthritis & Rheumatism, vol. 65, no. 1, pp. 24–27, 2013.
  67. G. R. Heiland, H. Appel, D. Poddubnyy et al., “High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 572–574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. S.-R. Kwon, M.-J. Lim, C.-H. Suh et al., “Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy,” Rheumatology International, vol. 32, no. 8, pp. 2523–2527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Appel, G. Ruiz-Heiland, J. Listing et al., “Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis,” Arthritis and Rheumatism, vol. 60, no. 11, pp. 3257–3262, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. H.-A. Chen, C.-H. Chen, Y.-J. Lin et al., “Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis,” Journal of Rheumatology, vol. 37, no. 10, pp. 2126–2132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. D. van der Heijde, R. Landewé, X. Baraliakos et al., “Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 58, no. 10, pp. 3063–3070, 2008. View at Publisher · View at Google Scholar · View at Scopus